<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605460</url>
  </required_header>
  <id_info>
    <org_study_id>INCMNSZ REF 917</org_study_id>
    <nct_id>NCT02605460</nct_id>
  </id_info>
  <brief_title>Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission</brief_title>
  <official_title>Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the disease free survival and the overall survival
      in patients with acute leukemia in first or second complete remission after administrating a
      CXCR4 antagonist, as a chemo sensitization strategy, plus chemotherapy as the conditioning
      regimen for autologous or allogeneic hematopoietic stem cell transplantation (HSCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the last decade, HSCT has become an efficient strategy for the treatment of many malignant
      and non-malignant hematological diseases, being the most common, according to the European
      Bone Marrow Transplantation (EBMT), acute leukemias. Both myeloid and lymphoid acute
      leukemias are considered malignant clonal diseases of the hematopoietic stem cells, and
      represent a therapeutic challenge due to the high relapse rate and mortality using
      conventional chemotherapy regimens. HSC reside mainly within the bone marrow, protected by a
      microenvironment or niche, which is perivascular, created partly by mesenchymal stromal cells
      and endothelial cells. Interactions between these cells and many adhesion molecules are
      considered a key factor for growing, transformation, and migration of neoplastic cells. The
      main pathway involved in the cellular transit regulation is chemokine receptor 4 (CXCR4) and
      its chemokine ligand 12 (CXCL12), responsible of mediating interactions between the HSC and
      stromal cells, and whose blocking through other cytokines and antagonists of the CXCR4
      receptor (plerixafor) favors chemotaxis and HSC output to peripheral blood. Such strategy has
      become an effective technique to increase mobilization and harvesting in patients undergoing
      stem cell transplantations.

      On the other hand, some preclinical studies have shown that the activation of CXCL12 pathway
      favors tumor growth, promoting survival and invasion of the malignant cells, recruiting
      stromal cells that facilitate their proliferation and promote angiogenesis directly. In such
      way, this pathway has been considered a therapeutic target to block their activity and
      inhibit tumor progression.

      Patients with acute leukemia in first or second complete remission undergoing autologous or
      allogeneic hematopoietic stem cell transplantation (HSCT), commonly present low response
      rates and low survival due to persistent minimal residual disease, despite conventional high
      dose chemotherapy regimens. It is necessary to create strategies to increase the destruction
      rate of neoplastic cells in patients with acute leukemia candidates to HSCT. Our hypothesis
      is that the administration of a CXCR4 antagonist as part of the conditioning regimen in
      patients with acute leukemia candidates to HSCT will allow the mobilization and sensitization
      of leukemia blast cells, eradicating efficiently the minimal residual disease, responsible of
      posterior relapse, and will achieve a higher response rate and survival of patients
      undergoing this procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <arm_group>
    <arm_group_label>Unique</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive reduced BUCY 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: CXCR4 Antagonist. Then they will undergo a Hematopoietic Stem Cell Transplantation (Autologous or Allogeneic)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>12mg/kg, ORAL, divided in 4 days, 3mg/kg/day ORAL, during days -7, -6, -5 y -4.</description>
    <arm_group_label>Unique</arm_group_label>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.</description>
    <arm_group_label>Unique</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CXCR4 Antagonist</intervention_name>
    <description>24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.</description>
    <arm_group_label>Unique</arm_group_label>
    <other_name>Plerixafor</other_name>
    <other_name>Mozobil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0</description>
    <arm_group_label>Unique</arm_group_label>
    <other_name>Bone Marrow Transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AML or ALL, candidates to HSCT

          -  Allogeneic HSCT: High risk AML in first complete remission (CR), AML in second CR, and
             ALL in first or second CR with a matched or half-matched (haploidentical) related or
             unrelated donor

          -  Autologous HSCT: Intermediate risk AML in first CR, ALL in first or second CR without
             a donor

          -  Normal liver function enzyme tests

          -  Preserved renal function

          -  ECOG ≤2 oR Karnofsky ≥80%

          -  FEVI &gt;40%

          -  Hb ≥ 10 g/dl, Absolute Neutrophil Count ≥ 1 x 103/mm3, and Platelets ≥ 100,000 /µL

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Patients not willing to participate or to sign the informed consent

          -  Patients who do not meet the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eucario Leon Rodriguez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eucario Leon Rodriguez, M.D.</last_name>
    <phone>525554870900</phone>
    <phone_ext>2255</phone_ext>
    <email>eucarios@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica M Rivera Franco, M.D.</last_name>
    <phone>525554870900</phone>
    <phone_ext>2254</phone_ext>
    <email>monrif90d@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eucario Leon Rodriguez, M.D.</last_name>
      <phone>525554870900</phone>
      <phone_ext>2255</phone_ext>
      <email>eucarios@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Monica M Rivera Franco, M.D.</last_name>
      <phone>525554870900</phone>
      <phone_ext>2254</phone_ext>
      <email>monrif90d@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Jantunen E. Novel strategies for blood stem cell mobilization: special focus on plerixafor. Expert Opin Biol Ther. 2011 Sep;11(9):1241-8. doi: 10.1517/14712598.2011.601737. Review.</citation>
    <PMID>21806478</PMID>
  </reference>
  <reference>
    <citation>DiPersio JF, Ho AD, Hanrahan J, Hsu FJ, Fruehauf S. Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant. 2011 Jul;17(7):943-55. doi: 10.1016/j.bbmt.2010.10.018. Epub 2010 Oct 22. Review.</citation>
    <PMID>20971201</PMID>
  </reference>
  <reference>
    <citation>Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res. 2011 Apr 15;17(8):2074-80. doi: 10.1158/1078-0432.CCR-10-2636. Epub 2011 Feb 24. Review.</citation>
    <PMID>21349998</PMID>
  </reference>
  <reference>
    <citation>Redjal N, Chan JA, Segal RA, Kung AL. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006 Nov 15;12(22):6765-71.</citation>
    <PMID>17121897</PMID>
  </reference>
  <reference>
    <citation>Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009 Jun 11;113(24):6206-14. doi: 10.1182/blood-2008-06-162123. Epub 2008 Dec 2.</citation>
    <PMID>19050309</PMID>
  </reference>
  <reference>
    <citation>Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 2012 Apr 26;119(17):3917-24. doi: 10.1182/blood-2011-10-383406. Epub 2012 Feb 2.</citation>
    <PMID>22308295</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Marrow Transplantation</keyword>
  <keyword>Conditioning Regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

